D-0511-2017 Class III Terminated
FDA drug recall D-0511-2017 was initiated by Teva Pharmaceuticals USA on Feb 17, 2017 and is designated Class III. Reason for recall: Failed Dissolution Specifications: low out of specification dissolution results found during stability testing. The recall status is terminated (terminated Feb 5, 2018). Affected quantity: 25,916 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 15, 2017
- Initiation Date
- Feb 17, 2017
- Termination Date
- Feb 5, 2018
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 25,916 cartons
Product description
Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.
Reason for recall
Failed Dissolution Specifications: low out of specification dissolution results found during stability testing.
Distribution pattern
Nationwide in the United States and Puerto Rico
Code information
Lot # 34025762A, Exp 06/17
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0511-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026